Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clustered nanobody–drug conjugates for targeted cancer therapy
Tiantian Wu, Manman Liu, Hai Huang, et al.
Chemical Communications (2020) Vol. 56, Iss. 65, pp. 9344-9347
Closed Access | Times Cited: 22

Showing 22 citing articles:

Nanobody—A versatile tool for cancer diagnosis and therapeutics
Manman Liu, Li Li, Duo Jin, et al.
Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology (2021) Vol. 13, Iss. 4
Closed Access | Times Cited: 123
The role of Platinum(IV)-based antitumor drugs and the anticancer immune response in medicinal inorganic chemistry. A systematic review from 2017 to 2022
Shihao Su, Yutong Chen, Pengfei Zhang, et al.
European Journal of Medicinal Chemistry (2022) Vol. 243, pp. 114680-114680
Closed Access | Times Cited: 43
Aptamers and nanobodies as alternatives to antibodies for ligand-targeted drug delivery in cancer
Dhruv Sanjanwala, Vandana Patravale
Drug Discovery Today (2023) Vol. 28, Iss. 5, pp. 103550-103550
Closed Access | Times Cited: 23
Enhancing Tumor Immunotherapy by Multivalent Anti‐PD‐L1 Nanobody Assembled via Ferritin Nanocage
Manman Liu, Duo Jin, Wenxin Yu, et al.
Advanced Science (2024) Vol. 11, Iss. 20
Open Access | Times Cited: 13
Molecular and functional insight into anti-EGFR nanobody: Theranostic implications for malignancies
Rajan K. Tripathy, Abhay H. Pande
Life Sciences (2024) Vol. 345, pp. 122593-122593
Closed Access | Times Cited: 9
Nanobodies as efficient drug-carriers: Progress and trends in chemotherapy
Sandeep Surendra Panikar, Nehla Banu, Jesse Haramati, et al.
Journal of Controlled Release (2021) Vol. 334, pp. 389-412
Closed Access | Times Cited: 41
Nanobody-Based EGFR-Targeting Immunotoxins for Colorectal Cancer Treatment
Javier Narbona, Luisa Hernández-Baraza, Rubén G. Gordo, et al.
Biomolecules (2023) Vol. 13, Iss. 7, pp. 1042-1042
Open Access | Times Cited: 15
Nanobody-based drug delivery systems for cancer therapy
Lin Liu, Bin Tu, Yao Sun, et al.
Journal of Controlled Release (2025) Vol. 381, pp. 113562-113562
Closed Access
Nanobodies targeting the tumor microenvironment and their formulation as nanomedicines
Liudmyla Maksymova, Yannick A. Pilger, Lutz Nuhn, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access
Research progress on nanobodies in the diagnosis and treatment of natural toxin poisoning
Xiwei Wang, Zenglin Yin, Nan Liu, et al.
Nano Today (2025) Vol. 62, pp. 102711-102711
Closed Access
Emerging applications of nanobodies in cancer therapy
Robin Maximilian Awad, Fien Meeus, Hannelore Ceuppens, et al.
International review of cell and molecular biology (2022), pp. 143-199
Open Access | Times Cited: 17
Engineering CpG‐ASO‐Pt‐Loaded Macrophages (CAP@M) for Synergistic Chemo‐/Gene‐/Immuno‐Therapy
Yuqi Wang, Lingpu Zhang, Yan Liu, et al.
Advanced Healthcare Materials (2022) Vol. 11, Iss. 15
Open Access | Times Cited: 16
Conjugation of oxaliplatin with PEGylated-nanobody for enhancing tumor targeting and prolonging circulation
Li Li, Yang Zhu, Manman Liu, et al.
Journal of Inorganic Biochemistry (2021) Vol. 223, pp. 111553-111553
Closed Access | Times Cited: 22
Stable high-oxidation-state complex in situ Mn(v)–Mn(iii) transition to achieve highly efficient cervical cancer therapy
Hanjie Zhang, Yuequn Zhang, Jianrong Cao, et al.
Chemical Communications (2022) Vol. 58, Iss. 23, pp. 3759-3762
Closed Access | Times Cited: 11
Reduction-responsive dextran-based Pt(IV) nano-prodrug showed a synergistic effect with doxorubicin for effective melanoma treatment
Lin An, Yuxi Jia, Jinran Li, et al.
International Journal of Biological Macromolecules (2023) Vol. 233, pp. 123277-123277
Closed Access | Times Cited: 4
Functionalized nanobody-based delivery systems for cancer diagnosis and therapeutic applications
Govindarajan Venkat Kumar, Amanda‐Lee E. Manicum, Tendai Makwikwi, et al.
Elsevier eBooks (2024), pp. 283-305
Closed Access | Times Cited: 1
Nanobodies: new avenue to treat kidney disease
Nicola Wanner, Thomas Watts Eden, Nastassia Liaukouskaya, et al.
Cell and Tissue Research (2021) Vol. 385, Iss. 2, pp. 445-456
Open Access | Times Cited: 9
Site-selective and inducible acylation of thrombin using aptamer-catalyst conjugates
Jordi F. Keijzer, Judith J. Firet, Bauke Albada
Chemical Communications (2021) Vol. 57, Iss. 96, pp. 12960-12963
Open Access | Times Cited: 9
Antibody-platinum (IV) prodrugs conjugates for targeted treatment of cutaneous squamous cell carcinoma
Xiangye Yin, Zhuang Ying-jie, Haiqin Song, et al.
Journal of Pharmaceutical Analysis (2023) Vol. 14, Iss. 3, pp. 389-400
Open Access | Times Cited: 2
Application of Biocatalysis for Protein Bioconjugation
Thomas A. King, Laura Rodríguez Pérez, Sabine L. Flitsch
Elsevier eBooks (2023), pp. 389-437
Closed Access | Times Cited: 1
Single domain antibodies specific for HER2 dimerization domain effectively disrupts HER2 dimerization
Ahmad Najafi, Reza Valadan, Hossein Asgarian‐Omran, et al.
International Immunopharmacology (2023) Vol. 124, pp. 110999-110999
Closed Access
The Potential Applicability of Single-Domain Antibodies (VHH): From Checkpoint Blockade to Infectious Disease Therapy
Pouya Safarzadeh Kozani, Pooria Safarzadeh Kozani, Fatemeh Rahbarizadeh
Trends in Medical Sciences (2021) Vol. 1, Iss. 2
Open Access
Page 1

Scroll to top